Beverly S. Mitchell

Overview

Best Publications

• Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

  Robert Z. Orlowski;Thomas E. Stinchcombe;Beverly S. Mitchell;Thomas C. Shea

  945
  Citations

• Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

  K. R. Rai;C. E. Freter;R. J. Mercier;M. R. Cooper

  454
  Citations

• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

  Robert Z. Orlowski;Robert Z. Orlowski;Peter M. Voorhees;Peter M. Voorhees;Reynaldo A. Garcia;Reynaldo A. Garcia;Melissa D. Hall;Melissa D. Hall

  406
  Citations

• Association of DNA Polymerase μ (pol μ) with Ku and Ligase IV: Role for pol μ in End-Joining Double-Strand Break Repair

  Kiran N. Mahajan;Stephanie A. Nick McElhinny;Beverly S. Mitchell;Dale A. Ramsden

  404
  Citations

• The 5′-nucleotidases as regulators of nucleotide and drug metabolism

  Sally Anne Hunsucker;Beverly S. Mitchell;Jozef Spychala

  381
  Citations

• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

  Daniel J. DeAngelo;Daohai Yu;Jeffrey L. Johnson;Steven E. Coutre

  361
  Citations

• Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

  Beverly S. Mitchell;Edwin Mejias;Peter E. Daddona;William N. Kelley

  284
  Citations

• Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies

  J. Kurtzberg;T.J. Ernst;M.J. Keating;V. Gandhi

  229
  Citations

• Cloning and expression of human deoxycytidine kinase cDNA.

  E G Chottiner;D S Shewach;N S Datta;E Ashcraft

  225
  Citations

• Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.

  L. A. Turka;J. D. Dayton;G. Sinclair;C. B. Thompson

  206
  Citations

• Future cancer research priorities in the USA: a Lancet Oncology Commission

  Elizabeth M. Jaffee;Chi Van Dang;Chi Van Dang;David B. Agus;Brian M. Alexander

  205
  Citations

• Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts

  Irene S. Kazmers;Beverly S. Mitchell;Peter E. Dadonna;Linda L. Wotring

  193
  Citations

• Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.

  Janet K. Owens;Donna S. Shewach;Buddy Ullman;Beverly S. Mitchell

  188
  Citations

• Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases

  Jozef Spychala;Nabanita S. Datta;Kenji Takabayashi;Milton Datta

  187
  Citations

• Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance.

  Sally Anne Hunsucker;Jozef Spychala;Beverly S. Mitchell

  168
  Citations

• Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo.

  Yoshinobu Manome;Patrick Y. Wen;Yonghe Dong;Toshihide Tanaka

  161
  Citations

• Regulation of the Interaction of Inosine Monophosphate Dehydrogenase with Mycophenolic Acid by GTP

  Yan Shan Ji;Jing Jin Gu;Alexander M. Makhov;Jack D. Griffith

  159
  Citations

• Role of Estrogen Receptor in the Regulation of Ecto-5′-Nucleotidase and Adenosine in Breast Cancer

  Jozef Spychala;Eduardo Lazarowski;Anna Ostapkowicz;Lanier H. Ayscue

  155
  Citations

• ATP depletion as a consequence of adenosine deaminase inhibition in man.

  Martin F. E. Siaw;Beverly S. Mitchell;Charles A. Koller;Mary Sue Coleman

  155
  Citations

• The proteasome--an emerging therapeutic target in cancer.

  Beverly S. Mitchell

  154
  Citations